Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study

Makoto Uchiyama, Daiji Kambe, Yumiko Imadera, Yu Kajiyama, Hiroki Ogo, Naohisa Uchimura, Makoto Uchiyama, Daiji Kambe, Yumiko Imadera, Yu Kajiyama, Hiroki Ogo, Naohisa Uchimura

Abstract

Rationale: Novel compound with potent antagonistic activity against orexin receptors may be new treatment option for patients with insomnia.

Objective: The aim was to investigate the efficacy and safety of single oral doses of the dual orexin receptor antagonist TS-142 in patients with insomnia.

Methods: This multicenter, double-blind, crossover randomized clinical trial included non-elderly patients with insomnia. Patients were randomized to receive single doses of placebo and TS-142 at doses of 5, 10, and 30 mg in one of four different sequences, with a 7-day washout period between treatments. Primary efficacy endpoints were latency to persistent sleep (LPS) and wake time after sleep onset (WASO) measured by polysomnography.

Results: Twenty-four patients were included (mean age 50.3 ± 10.5 years; mean duration of insomnia 5.71 ± 8.68 years). Least-squares mean differences (95% confidence interval) from placebo in LPS with 5, 10, and 30 mg TS-142 were - 42.38 (- 60.13, - 24.63), - 42.10 (- 60.02, - 24.17), and - 44.68 (- 62.41, - 26.95) minutes, respectively (all p < 0.001). Least-squares mean differences (95% confidence interval) from placebo in WASO with 5, 10, and 30 mg TS-142 were - 27.52 (- 46.90, - 8.14), - 35.44 (- 55.02, - 15.87), and - 54.69 (- 74.16, - 35.23) minutes, respectively (all p < 0.01). Self-reported aspects of sleep initiation and sleep quality, determined using the Leeds Sleep Evaluation Questionnaire (LSEQ), were also improved with TS-142 administration versus placebo. TS-142 was well tolerated; all adverse events were mild or moderate and none were serious.

Conclusion: Single-dose TS-142 was well tolerated and had clinically relevant effects on objective and subjective sleep parameters in patients with insomnia.

Clinical trial registration: JapicCTI173570 (www.

Clinicaltrials: jp); NCT04573725 (www.

Clinicaltrials: gov).

Keywords: Clinical Trial; Insomnia; ORN0829; Orexin; Orexin Receptor Antagonists; Polysomnography; Randomized Controlled Trial; Sleep Initiation and Maintenance Disorders; Sleep diary; TS-142.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study design. EOS, end of study; PSG, polysomnography; Seq, sequence
Fig. 2
Fig. 2
Patient disposition. The orders of administration in each sequence are described in methods.
Fig. 3
Fig. 3
Least-squares mean difference in objective and subjective sleep parameters with TS-142 compared with placebo. Least-squares mean difference in objective (A and B) and subjective (C and D) sleep parameters with TS-142 compared with placebo; (A) latency to persistent sleep (LPS); (B) wake time after sleep onset (WASO); (C) subjective sleep latency (sSL); (D) subjective wake time after sleep onset (sWASO). Graphs show point estimates (filled circles or opened diamonds) with 95% confidence intervals (vertical bar)

References

    1. Agravat A. ‘Z’-hypnotics versus benzodiazepines for the treatment of insomnia. Prog Neurol Psych. 2018;22:26–29. doi: 10.1002/pnp.502.
    1. Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990;52:29–37. doi: 10.3109/00207459008994241.
    1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA. American Psychiatric Publishing10.1176/appi.books.9780890425596
    1. Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135:10–19. doi: 10.1016/j.jad.2011.01.011.
    1. Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther. 2017;362:287–295. doi: 10.1124/jpet.117.241422.
    1. Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, et al. Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J Pharmacol Exp Ther. 2015;354:471–482. doi: 10.1124/jpet.115.225466.
    1. Brisbare-Roche C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13:150–155. doi: 10.1038/nm1544.
    1. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33:414–420. doi: 10.2337/dc09-1124.
    1. Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H–1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53:5320–5332. doi: 10.1021/jm100541c.
    1. De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, et al. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J Psychopharmacol. 2018;32:668–677. doi: 10.1177/0269881118773745.
    1. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95:322–327. doi: 10.1073/pnas.95.1.322.
    1. DiBonaventura M, Richard L, Kumar M, Forsythe A, Flores NM, Moline M. The association between insomnia and insomnia treatment side effects on health status, work productivity, and healthcare resource use. PLoS ONE. 2015;10:e0137117. doi: 10.1371/journal.pone.0137117.
    1. Freeman D, Sheaves B, Waite F, Harvey AG, Harrison PJ. Sleep disturbance and psychiatric disorders. Lancet Psychiatry. 2020;7:628–637. doi: 10.1016/S2215-0366(20)30136-X.
    1. Futamura A, Suzuki R, Tamura Y, Kawamoto H, Ohmichi M, Hino N, et al. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia. Bioorg Med Chem. 2020;28:115489. doi: 10.1016/j.bmc.2020.115489.
    1. Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, et al. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci. 2013;14:90. doi: 10.1186/1471-2202-14-90.
    1. Hägg SA, Torén K, Lindberg E. Role of sleep disturbances in occupational accidents among women. Scand J Work Environ Health. 2015;41:368–376. doi: 10.5271/sjweh.3495.
    1. Han Y, Yuan K, Zheng Y, Lu L. Orexin receptor antagonists as emerging treatments for psychiatric disorders. Neurosci Bull. 2020;36:432–448. doi: 10.1007/s12264-019-00447-9.
    1. Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265–2274. doi: 10.1212/WNL.0b013e31827688ee.
    1. Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79:136–148. doi: 10.1016/j.biopsych.2014.10.003.
    1. Hertenstein E, Gabryelska A, Spiegelhalder K, Nissen C, Johann AF, Umarova R, et al. Reference Data for Polysomnography-Measured and Subjective Sleep in Healthy Adults. J Clin Sleep Med. 2018;14:523–532. doi: 10.5664/jcsm.7036.
    1. Hindmarch IA. 1,4-benzodiazepine, temazepam (K 3917), its effect on some psychological parameters of sleep and behaviour. Arzneimittelforschung. 1975;25:1836–1839.
    1. Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018;14:1399–1408. doi: 10.5664/jcsm.7282.
    1. Kay-Stacey M, Attarian H. Advances in the management of chronic insomnia. BMJ. 2016;353:i2123. doi: 10.1136/bmj.i2123.
    1. Khan MS, Aouad R. The effects of insomnia and sleep loss on cardiovascular disease. Sleep Med Clin. 2017;12:167–177. doi: 10.1016/j.jsmc.2017.01.005.
    1. Kling RN, McLeod CB, Koehoorn M. Sleep problems and workplace injuries in Canada. Sleep. 2010;33:611–618. doi: 10.1093/sleep/33.5.611.
    1. Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol. 2014;171:314–331. doi: 10.1111/bph.12324.
    1. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev. 2010;14:69–82. doi: 10.1016/j.smrv.2009.07.004.
    1. Laugsand LE, Strand LB, Vatten LJ, Janszky I, Bjørngaard JH. Insomnia symptoms and risk for unintentional fatal injuries–the HUNT Study. Sleep. 2014;37:1777–1786. doi: 10.5665/sleep.4170.
    1. Mahoney CE, Mochizuki T, Scammell TE (2020) Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. Sleep43:zsz302. 10.1093/sleep/zsz302
    1. Mieda M. The roles of orexins in sleep/wake regulation. Neurosci Res. 2017;118:56–65. doi: 10.1016/j.neures.2017.03.015.
    1. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epidemiology of insomnia: a longitudinal study in a UK population. Sleep. 2007;30:274–280. doi: 10.1093/sleep/30.3.274.
    1. Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, et al. Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med. 2017;13:1289–1299. doi: 10.5664/jcsm.6800.
    1. Ohayon MM, Krystal A, Roehrs TA, Roth T, Vitiello MV. Using difficulty resuming sleep to define nocturnal awakenings. Sleep Med. 2010;11:236–241. doi: 10.1016/j.sleep.2009.11.004.
    1. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology. 1980;71:173–179. doi: 10.1007/BF00434408.
    1. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8:171–181. doi: 10.1038/nrn2092.
    1. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573–585. doi: 10.1016/S0092-8674(00)80949-6.
    1. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437:1257–1263. doi: 10.1038/nature04284.
    1. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307–349. doi: 10.5664/jcsm.6470.
    1. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487–504. doi: 10.5664/jcsm.27286.
    1. Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, et al. The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. J Pharmacol Exp Ther. 2017;362:489–503. doi: 10.1124/jpet.117.241596.
    1. Treves N, Perlman A, Kolenberg Geron L, Asaly A, Matok I. Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. Age Ageing. 2018;47:201–208. doi: 10.1093/ageing/afx167.
    1. Uchiyama M, Kambe D, Imadera Y, Sunaga H, Hasegawa S, Nogi T, et al. (2020) Efficacy and safety of single dose of TS-142, a novel and potent dual orexin receptor antagonist, in insomnia patients (abstract 0146). Sleep43:A58-A. 10.1093/sleep/zsaa056.144
    1. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32:491–497. doi: 10.1093/sleep/32.4.491.
    1. Weschsler D. The measurement and appraisal of adult intelligence. 1. Baltimore: The Williams and Wilkins Company; 1939.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever